GlassScriptPhysician profile
Alosh Madala
NPI 1285894030
$2,472.62
in general payments reported to CMS, 2019-2025
41 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $31.86 · 2021: $278 · 2022: $618 · 2023: $763 · 2024: $250 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $311.67 | 2022-2025 | Aquabeam System |
| Ucb, INC. | $282.08 | 2022-2024 | Briviact, Nayzilam |
| Acadia Pharmaceuticals INC | $213.37 | 2022-2024 | Nuplazid |
| Astellas Pharma US INC | $166.75 | 2019-2022 | |
| Davol INC. | $147.61 | 2023 | Arista Ah Flexitip |
| Emd Serono, INC. | $137.95 | 2022-2024 | Mavenclad |
| Profound Medical Corp. | $103.52 | 2025 | Tulsa-Pro |
| Pfizer INC. | $99.61 | 2019-2021 | |
| Kyowa Kirin, INC. | $94.92 | 2022-2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $87.73 | 2021-2023 | Austedo Xr, Austedo |
| Biogen, INC. | $73.49 | 2021-2022 | |
| Coloplast Corp | $66.04 | 2019-2024 | |
| Rochester Medical Corporation | $45.88 | 2021-2022 | |
| Convatec INC. | $39.00 | 2021-2022 | |
| Olympus America INC. | $38.66 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $37.61 | 2025 | |
| Urovant Sciences INC | $34.32 | 2021-2022 | |
| Boston Scientific Corporation | $33.79 | 2022-2023 | Vercise |
| Novartis Pharmaceuticals Corporation | $32.06 | 2023 | |
| Antares Pharma, INC. | $29.63 | 2019-2021 | |
| Corium, LLC | $28.33 | 2023 | Adlarity |
| 180 Medical, INC. | $27.59 | 2021 | |
| Sumitomo Pharma America, INC. | $26.95 | 2023-2024 | Aptiom |
| Agiliti Surgical, INC. | $26.50 | 2022 | |
| Abbvie INC. | $26.42 | 2019 | |
| Neurocrine Biosciences, INC. | $25.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.20 | 2023 | Nuedexta |
| Grifols USA, LLC | $22.83 | 2023 | Gamunex-C |
| Allergan, INC. | $20.53 | 2019 | |
| Intuitive Surgical, INC. | $19.53 | 2019 | |
| Kerecis Limited | $15.31 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Telix Pharmaceuticals | $15.31 | 2023 | Illuccix |
| Endo Pharmaceuticals INC. | $14.85 | 2021 | |
| Medtronic, INC. | $14.49 | 2023 | Percept PC Brainsense |
| Laborie Medical Technologies Corp. | $14.13 | 2025 | Aquarius Lt |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2022 | |
| Medtronic USA, INC. | $13.37 | 2020 | |
| Myovant Sciences INC. | $11.89 | 2021 | |
| Teleflex LLC | $11.83 | 2021 | |
| Amgen INC. | $11.56 | 2019 | |
| Ethicon US, LLC | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alosh Madala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.